The roles of right ventricular (RV) structure and function in health and disease have not been well studied. Although historical animal studies suggested that the RV did not contribute importantly to cardiac function, more recent studies of patients with diseases such as pulmonary arterial hypertension and congestive heart failure have shown that RV size and ejection fraction are independent predictors of survival. Whether the RV has an important role in communitybased adults is unknown. This study showed that the presence of RV hypertrophy (measured by magnetic resonance imaging) in adults without clinical cardiovascular disease at baseline was associated with an increased risk of heart failure or cardiovascular death. This association held after accounting for left ventricular mass but was stronger in participants with lower left ventricular mass. There are several explanations for this finding. Patients with left ventricular hypertrophy may have an increased risk of events directly attributable to the left ventricular pathology, explaining why the effect of RV hypertrophy is stronger in its absence. RV hypertrophy could indicate a higher risk of heart failure by serving as a sensitive barometer of left ventricular function. Increased RV afterload may also be seen in conditions such as sleep-disordered breathing and/or subclinical pulmonary vascular disease, which could cause both RV hypertrophy and an increased risk of events. Alternatively, RV hypertrophy could directly contribute to the onset of heart failure. Clinical cardiovascular disease-free adults with RV hypertrophy are at higher overall risk of heart failure and death, warranting further studies of mechanisms and potential treatment interventions. See p 1681.
Prospective Study of Restless Legs Syndrome and Coronary Heart Disease Among Women
Restless legs syndrome (RLS), also known as Willis Ekbom disease, is a common, bothersome sensorimotor disorder characterized by an almost irresistible urge to move the legs, accompanied by unpleasant sensation in the legs and a worsening of the symptoms in the evening or during the night. Cross-sectional epidemiological studies have suggested a positive association between RLS and coronary heart disease (CHD), but this association was not confirmed by 2 subsequent prospective studies. In this article, the association was prospectively examined, taking into account the duration of RLS symptoms based on the Nurses' Health Study, a well-characterized prospective cohort comprising 70 977 women. We found that women with physician-diagnosed RLS, especially those with longer disease duration, tend to have a higher risk of developing CHD. In this analysis, RLS preceded the development of CHD, which suggests but cannot prove a causal role for RLS in CHD. The results suggest that the long-term impact of RLS or RLS-associated conditions may contribute to cardiovascular disease. If the association between RLS and CHD is confirmed in future studies, we suggest that clinicians should screen for RLS because it may be helpful in judging a patient's cardiovascular risk combined with other known risk factors for CHD. See p 1689.
Modeling Supravalvular Aortic Stenosis Syndrome With Human Induced Pluripotent Stem Cells
Currently, treatment of proliferation-based pathologies relies on drugs like rapamycin that may have a broad impact on patient physiology. Such treatment risks unintended effects in targeted and off-target cell types, potentially initiating new dysfunction. To effectively treat patients, it is critical to root out the mechanisms of proliferative diseases so that treatments can be developed to specifically attack the existing pathology without risking further complication. This study shows for the first time that the hyperproliferation in smooth muscle cells (SMCs) that causes supravalvular aortic stenosis (SVAS) syndrome is, in turn, accompanied by a marked decrease in actin filament bundle formation and an increase in migration. More important, we have shown that treatment with exogenous elastin monomers rescues the actin filament bundle formation in supravalvular aortic stenosis cells. With these results taken together, it can be hypothesized that a switch from a contractile to a proliferative phenotype in smooth muscle cells is caused by an elastin deficiency. Induced, pluripotent stem cell models of proliferative diseases such as the one used here should prove valuable in the search for candidate pathways and pharmaceutical agents. As a result, clinical interventions focusing on the enhancement of smooth muscle cell actin filament bundle formation and/or elastin production of affected vessel walls promise higher efficacy and lower risk to the patient than current treatments. There are several avenues through which such interventions can be realized, but given a candidate drug specific to actin filament bundle formation and/or elastin production, the goal of curing deadly proliferation-based smooth muscle cell diseases appears to be close at hand. See p 1695.
Carnitine Palmitoyltransferase-1b Deficiency Aggravates Pressure Overload-Induced Cardiac Hypertrophy Caused by Lipotoxicity
The present study based on a mouse model with heterozygous carnitine palmitoyltransferase-1b (CPT1b) deficiency demonstrated that CPT1b deficiency is detrimental to the heart under left ventricular pressure-overload conditions. This finding contrasts with the common view that fatty acid oxidation (FAO) depression may be beneficial for the heart in the progression of cardiac hypertrophy and heart failure. It is recognized that myocardial FAO provides the majority of cardiac energy in a normal heart. However, the more oxygen-consuming FAO becomes a burden for the heart under hypertrophy and heart failure conditions. Consequently, the heart switches to use glucose as the main fuel with better energy efficiency. Therefore, compounds of FAO inhibitors targeting various FAO steps for the treatment of cardiac hypertrophy and heart failure have been developed and tested. Some beneficial effects have been shown in small clinical trials, especially for CPT1 inhibitors. However, this therapy is also associated with adverse effects. These untoward effects limit clinical utility and highlight the need for more preclinical studies. A major hurdle for the clinical use of this class of drugs is the lack of understanding of the potential detrimental effects of FAO deficiency in the heart under pathological conditions. Therefore, the present studies based on a genetic mouse model should provide definitive insights into the potential problems with the clinical use of this class of drugs to treat cardiac hypertrophy and heart failure. See p 1705.
A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention: The PROTECT II Study
Complex percutaneous coronary intervention with hemodynamic support may offer an effective therapy for high-risk patients with multivessel or unprotected left main lesions. In the PROTECT II trial we randomly assigned 452 high-risk patients undergoing percutaneous coronary intervention to hemodynamic support with intra-aortic balloon counterpulsation or a percutaneous (Impella 2.5) axial flow left ventricular assist device. Primary outcome was incidence of major adverse events at 30 days with prospectively planned follow-up to 90 days. The trial was able to enroll the most ill population of symptomatic ischemic heart disease patients ever enrolled in a percutaneous coronary intervention trial. These patients were highly symptomatic, 66% were in New York Heart Association class III or IV, 87% had a history of heart failure, 51% had diabetes mellitus, 26% had renal insufficiency, and ejection fraction was 24%. Despite these extreme risk features, the reported 30-day mortality of 6.7% is comparable to predicted surgical models. Angiography success was high, whereas stroke/transient ischemic attack and incidence of renal failure rates were low. At 90 days follow-up, 68% of patients had improvement in symptom status with 74% of patients either class I or class II. The trial was terminated prematurely because of the data safety monitoring board's determination of futility. At 30 days, no difference in incidence of major adverse events occurred for either intent-to-treat or per protocol analysis. Planned follow-up at 90 days reveals a strong trend of benefit for Impella-treated patients (Pϭ0.066, intent-to-treat) and significant for patients who actually qualified (Pϭ0.023, per protocol). See p 1717.
Therapeutic Impact of Follistatin-Like 1 on Myocardial Ischemic Injury in Preclinical Models
Heart tissue secretes a variety of bioactive molecules, also known as cardiokines, that modulate the cellular processes in the heart. Follistatin-like 1 (FSTL1) is a cardiokine that is upregulated in the heart in response to ischemic insult. In the present study, we investigated the therapeutic impact of FSTL1 on acute cardiac injury in small and large preclinical animal models of ischemia/reperfusion. Systemic delivery of recombinant human FSTL1 protein to mice led to reductions of myocardial injury and dysfunction. Furthermore, intracoronary injection of human FSTL1 protein attenuated myocar-dial infarction and improved cardiac function in pigs after ischemia/ reperfusion. The beneficial actions of FSTL1 were associated with suppression of apoptosis and inflammation in the ischemic heart. FSTL1 promoted AMP-activated protein kinase signaling pathways in the ischemic heart, thereby leading to a reduction of inflammation and apoptosis. FSTL1 also antagonized the proinflammatory and proapoptotic functions of bone morphogenetic protein-4. Therefore, FSTL1 can prevent myocardial ischemia/reperfusion injury by inhibiting apoptosis and inflammatory response through modulation of AMP-activated protein kinase-and bone morphogenetic protein-4dependent mechanisms. Our observations suggest that FSTL1 could represent a novel therapeutic target for the treatment of postmyocardial infarction, acute coronary syndrome. See p 1728.
Conditional Targeting of Tumor Necrosis Factor Receptor-Associated Factor 6 Reveals Opposing Functions of Toll-Like Receptor Signaling in Endothelial and Myeloid Cells in a Mouse Model of Atherosclerosis
Atherosclerosis is the major cause of death in Westernized societies, being the underlying cause of severe cardiovascular diseases such as heart attack and stroke. Toll-like receptor (TLR) signaling has been implicated as a critical pathogenic factor in atherosclerosis and has attracted increased interest as a potential therapeutic target for the treatment of atherosclerosis. Our in vivo studies showed that TLR signaling exerts surprisingly diverse functions in endothelial cells and macrophages differentially affecting the development of atherosclerosis. Endothelial cell-specific inhibition of TLR signaling reduced atherosclerosis severity in female mice by inhibiting nuclear factor-B activation and the expression of proinflammatory mediators by the vascular endothelium in response to oxidized lipids, resulting in less efficient recruitment of monocytes into the developing plaques. In contrast, myeloid cell-specific inhibition of TLR signaling surprisingly resulted in more severe atherosclerosis by compromising the antiinflammatory properties, endoplasmic reticulum stress survival responses, and efferocytosis capacity of macrophages. Collectively, these results revealed a previously unappreciated functional diversity of TLR signaling in 2 cell types that are critical for the development of atherosclerosis. In response to modified lipids, TLR signaling exerts proatherogenic functions in endothelial cells in female mice by inducing the expression of proinflammatory mediators facilitating monocyte recruitment. In contrast, TLR signaling in macrophages is atheroprotective by inducing interleukin-10 expression, suppressing endoplasmic reticulum stress-induced macrophage death, and stimulating efferocytosis. These findings urge caution in the systemic application of TLR signaling inhibitors in atherosclerosis and suggest that strategies specifically targeting endothelial cells would have a greater therapeutic potential. See p 1739.
